WO2010076349A2 - Procedimiento para la obtención de células madre mesenquimales a partir de la fracción mononuclear de la médula ósea humana - Google Patents
Procedimiento para la obtención de células madre mesenquimales a partir de la fracción mononuclear de la médula ósea humana Download PDFInfo
- Publication number
- WO2010076349A2 WO2010076349A2 PCT/ES2009/000547 ES2009000547W WO2010076349A2 WO 2010076349 A2 WO2010076349 A2 WO 2010076349A2 ES 2009000547 W ES2009000547 W ES 2009000547W WO 2010076349 A2 WO2010076349 A2 WO 2010076349A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture
- cells
- stem cells
- mesenchymal stem
- days
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 24
- 210000000130 stem cell Anatomy 0.000 title abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 39
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 37
- 239000001963 growth medium Substances 0.000 claims description 27
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- 210000005087 mononuclear cell Anatomy 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000001143 conditioned effect Effects 0.000 claims description 2
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 210000002798 bone marrow cell Anatomy 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- -1 CD31 Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0666—Mesenchymal stem cells from hair follicles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
Definitions
- the present invention relates to a process for obtaining mesenchymal stem cells. More specifically, the present invention relates to a method of obtaining mesenchymal stem cells from the mononuclear fraction of human bone marrow cells. Said method comprises the stages of obtaining said bone marrow mononuclear fraction, the stage of recovery and pre-expansion of the mesenchymal stem cells, and the stage of expansion of the mesenchymal stem cells until obtaining the necessary clinical dose for its possible Therapeutic use.
- CMM Mesenchymal stem cells
- the bone marrow mononuclear fraction (CMN) is obtained by a separation operation based on the centrifugation of blood from the bone marrow.
- CMN is a heterogeneous set of cells, among which, in addition to mesenchymal stem cells, hematopoietic stem cells can be found. These two populations are in a very low concentration with respect to mature hematopoietic cells, also present in CMN.
- Fridenshtein et al. (Fridenshtein AJ, Deriglazova UF, Kulagina NN et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp. Hematol. 1974 VoI. 2. P. 83-92) obtained for the first time mesenchymal stem cells from bone marrow, based on the ability of mesenchymal stem cells to adhere to plastic surfaces, property that most hematopoietic cells do not possess.
- the disadvantage of this method is the low yield obtained in the recovery of mesenchymal cells attributable to the low prevalence of this cell type in the bone marrow, which is estimated between 0.001 to 0.01% (Alhadlag A and Mao J. Mesenchymal Stem Cells: Isolation and Therapeutics, Stem Cells and Development 2004. 13: 436-448 (3)
- adherence to plastics has been established as a starting point to continue improving the methods of obtaining mesenchymal stem cells.
- Another disadvantage of this method is that to obtain sufficient amounts of mesenchymal stem cells for clinical use, the cells must be cultured between 4 and 6 weeks, and even in some circumstances, such as in patients with diseases of bone metabolism, time Cultivation may be higher.
- the reason why these high culture times are needed, as mentioned above, is the small amount of mesenchymal cells that can be obtained from the bone marrow.
- a long period of cell culture can increase the risk of contamination and significantly increases the maintenance costs of the culture.
- the number of duplications increases, there is a risk that the cells lose multipotentiality or enter senescence, which compromises their therapeutic capacity.
- the methodology commonly used to find a decrease in the culture times of mesenchymal cells focuses on factors such as supplements of the culture medium, the type of plastic surface, the sowing dose and the culture media used (Sotiropolou PA, Pérez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006; 24: 462-471).
- An objective of the present invention is to give Knowing a method of ex vivo culture of mesenchymal stem cells from human bone marrow in which the time and number of duplications necessary for obtaining the clinical dose of mesenchymal stem cells is reduced, when compared to traditional methods.
- This procedure is based on the synergistic effect from combining very specific conditions of isolation of mesenchymal cells from the mononuclear fraction of bone marrow, with the use of human serum from blood group AB as a supplement to the culture medium. This is used instead of expensive and poorly reproducible fetal bovine serum.
- human AB serum has the advantages of being cheaper and having greater reproducibility than fetal bovine serum.
- the proposed isolation conditions facilitate the recovery of a greater number of mesenchymal cells of the mononuclear fraction with respect to the conditions used in conventional strategies. This fact is of special relevance if one takes into account that the higher the initial number of available isolated mesenchymal cells, the less time and resources required to obtain the required clinical dose.
- Another objective of the present invention is to provide a method that allows for an identical backup of the stem cells.
- mesenchymal which have the same characteristics of the initial mesenchymal stem cells in terms of proliferation and differentiation capacity.
- the method of the present invention can be applied to obtain mesenchymal cells from other sources, such as adipose tissue, pancreas, liver, skeletal muscle, dermis, synovial membrane, trabecular bone, umbilical cord blood, lung tissue, dental pulp and periodontal ligament.
- sources such as adipose tissue, pancreas, liver, skeletal muscle, dermis, synovial membrane, trabecular bone, umbilical cord blood, lung tissue, dental pulp and periodontal ligament.
- the initial treatment of the sample will be different, adapting for each cell type that is used as the source.
- an objective of the present invention is to provide a method for obtaining mesenchymal stem cells from the human bone marrow mononuclear fraction, obtained by density gradient centrifugation, characterized in that it comprises stages of: a) Recovery and pre-expansion of mesenchymal stem cells, through a primary culture, in which the bone marrow mononuclear cells are sown in DMEM culture medium supplemented with human AB serum (10%) following the following scheme of culture:
- trypsinization of the primary culture is performed at 12 days. These cells are conditioned for transfer to the operating room.
- the culture medium used, both in primary and secondary culture is Dulbecco's Modified Eagle (DMEM) with a 10% human serum AB (v / v) supplement.
- DMEM Dulbecco's Modified Eagle
- the process of the present invention is advantageous in that it is possible to obtain a high number of mesenchymal stem cells, between 40.10 6 and 50.10 6 , with a reduced number of duplications, between 6 and 8, and a time interval (around 20 days) less than in traditional processes.
- an additional advantage is that it is achieved, by freezing the mesenchymal stem cells obtained in the secondary culture (step (b)), generating the required dose of cells in case of loss of the process due to accidental causes or having a copy Identical safety mesenchymal stem cells.
- the process of the present invention also has the additional advantages of simple handling and reduced costs, as extensive culture is not required, nor is fetal bovine serum used.
- bone marrow mononuclear cells were inoculated per square centimeter, obtained by centrifugation gradient of a bone marrow blood sample, in a 636 cm 2 commercial culture flask, containing DMEM medium supplemented with human AB serum
- the cells were cultured for 8 days, in which two changes of medium (days 3 and 6) were performed, using DMEM medium supplemented with human AB serum (10%) with a culture area / volume ratio of medium (3/1 ).
- Non-adhered cells in the primary culture which were seeded in a secondary culture (step (b)), were washed 5 days after the start of the secondary culture (step (b)) and the wash was discarded.
- the culture medium was changed and culture medium (DMEM supplemented with human AB serum (10%)) with a culture area / volume ratio of medium (3/1) was added.
- DMEM supplemented with human AB serum (10%) with a culture area / volume ratio of medium (3/1) was added.
- After 12 days a trypsinization of the culture was performed and between 3,10 6 and 6,10 6 mesenchymal stem cells were obtained with a purity of about 65%.
- the cells obtained were frozen in nitrogen tanks.
- the cells obtained in the primary culture showed an immunophenotypic profile with co-expression of markers 105, 90, 73 and lack of expression of the markers CD45, CD31, HLA-DR, usually associated with mesenchymal stem cells from bone marrow. In addition, the cells obtained showed differentiation capacity towards the bone lineage, a fact that puts I manifest the maintenance of multipotential capacity.
- the cells obtained in the secondary culture showed an immunophenotypic profile with co-expression of markers 105, 90, 73 and lack of expression of markers CD45, CD31, HLA-DR, usually associated to mesenchymal stem cells from bone marrow. In addition, the cells obtained showed differentiation capacity towards the bone and adipose lineage, thus maintaining their multipotential capacity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/124,916 US20110201111A1 (en) | 2009-01-02 | 2009-11-25 | Method for obtaining connective mesenchymal stem cells from the mononuclear fraction of human bone marrow |
MX2011003899A MX2011003899A (es) | 2009-01-02 | 2009-11-25 | Procedimiento para la obtencion de celulas madre mesenquimales a partir de la fraccion mononuclear de la medula osea humana. |
CN2009801572359A CN102388129A (zh) | 2009-01-02 | 2009-11-25 | 从人骨髓单核级分获得结缔间质干细胞的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200900005A ES2324011B1 (es) | 2009-01-02 | 2009-01-02 | Procedimiento para la obtencion de celulas madre mesenquimales a partir de la fraccion mononuclear de la medula osea humana. |
ESP200900005 | 2009-01-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010076349A2 true WO2010076349A2 (es) | 2010-07-08 |
WO2010076349A3 WO2010076349A3 (es) | 2013-01-03 |
Family
ID=40852644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2009/000547 WO2010076349A2 (es) | 2009-01-02 | 2009-11-25 | Procedimiento para la obtención de células madre mesenquimales a partir de la fracción mononuclear de la médula ósea humana |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110201111A1 (es) |
CN (1) | CN102388129A (es) |
CO (1) | CO6341651A2 (es) |
ES (1) | ES2324011B1 (es) |
MX (1) | MX2011003899A (es) |
WO (1) | WO2010076349A2 (es) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007037682A1 (en) * | 2005-09-28 | 2007-04-05 | Ipd-Therapeutics B.V. | Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics. |
WO2007085210A2 (en) * | 2006-01-25 | 2007-08-02 | Univerzita Karlova V Praze | Method of cultivation of human mesenchymal stem cells, particularly for the treatment of non-healing fractures, and bioreactor for carrying out this cultivation method |
CN101298606A (zh) * | 2008-02-14 | 2008-11-05 | 天津环宇商桥商务信息咨询有限公司 | 临床治疗用脐带胎盘间充质干细胞的制备储存和应用 |
-
2009
- 2009-01-02 ES ES200900005A patent/ES2324011B1/es not_active Expired - Fee Related
- 2009-11-25 WO PCT/ES2009/000547 patent/WO2010076349A2/es active Application Filing
- 2009-11-25 US US13/124,916 patent/US20110201111A1/en not_active Abandoned
- 2009-11-25 MX MX2011003899A patent/MX2011003899A/es active IP Right Grant
- 2009-11-25 CN CN2009801572359A patent/CN102388129A/zh active Pending
-
2011
- 2011-05-02 CO CO11053413A patent/CO6341651A2/es active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007037682A1 (en) * | 2005-09-28 | 2007-04-05 | Ipd-Therapeutics B.V. | Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics. |
WO2007085210A2 (en) * | 2006-01-25 | 2007-08-02 | Univerzita Karlova V Praze | Method of cultivation of human mesenchymal stem cells, particularly for the treatment of non-healing fractures, and bioreactor for carrying out this cultivation method |
CN101298606A (zh) * | 2008-02-14 | 2008-11-05 | 天津环宇商桥商务信息咨询有限公司 | 临床治疗用脐带胎盘间充质干细胞的制备储存和应用 |
Non-Patent Citations (3)
Title |
---|
KOCAOEMER, A. ET AL.: 'Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue.' STEM CELLS. vol. 25, no. 5, 2007, pages 1270 - 1278 * |
LE BLANC, K. ET AL.: 'Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum.' TRANSPLANTATION vol. 84, no. 8, 27 October 2007, pages 1055 - 1059 * |
PHADNIS, S.M. ET AL.: 'Human umbilical cord serum promotes growth, proliferation, as well as differentiation of human bones marrow-derived progenitor cells.' IN VITRO CELL. DEV. BIOL.- ANIMAL. vol. 42, November 2006, pages 283 - 286 * |
Also Published As
Publication number | Publication date |
---|---|
ES2324011A1 (es) | 2009-07-28 |
ES2324011B1 (es) | 2010-03-15 |
CO6341651A2 (es) | 2011-11-21 |
WO2010076349A3 (es) | 2013-01-03 |
MX2011003899A (es) | 2011-05-04 |
CN102388129A (zh) | 2012-03-21 |
US20110201111A1 (en) | 2011-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nakahara et al. | Culture‐expanded human periosteal‐derived cells exhibit osteochondral potential in vivo | |
CN101748096B (zh) | 亚全能干细胞、其制备方法及其用途 | |
Song et al. | Cultivation and identification of rat bone marrow‑derived mesenchymal stem cells | |
Li et al. | Donor's age dependent proliferation decrease of human bone marrow mesenchymal stem cells is linked to diminished clonogenicity | |
Wen et al. | Superior osteogenic capacity of different mesenchymal stem cells for bone tissue engineering | |
US7374937B1 (en) | Isolation and expansion of human marrow stromal cells | |
Danišovič et al. | Comparative analysis of mesenchymal stromal cells from different tissue sources in respect to articular cartilage tissue engineering | |
Hutson et al. | Rapid isolation, expansion, and differentiation of osteoprogenitors from full-term umbilical cord blood | |
IL280387B2 (en) | A method for producing cells derived from dental pulp | |
CN101831403B (zh) | 体外扩增人脐带胎盘间充质干细胞的方法 | |
CN1778905B (zh) | 一种脂肪间充质干细胞的分离培养方法及其应用 | |
Bougioukli et al. | Lentiviral Gene Therapy for Bone Repair Using Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells | |
Yamachika et al. | Bone regeneration from mesenchymal stem cells (MSCs) and compact bone-derived MSCs as an animal model | |
Soukup et al. | Mesenchymal stem cells isolated from the human bone marrow: cultivation, phenotypic analysis and changes in proliferation kinetics | |
CN105505865A (zh) | 一种脐带间充质干细胞的分离方法 | |
Liu et al. | The application and progress of stem cells in auricular cartilage regeneration: a systematic review | |
Okumachi et al. | Comparative analysis of rat mesenchymal stem cells derived from slow and fast skeletal muscle in vitro | |
CN101407790B (zh) | 一种增强人骨髓间充质干细胞旁分泌能力的处理方法 | |
CN102703380B (zh) | 亚全能干细胞、其制备方法及其用途 | |
ES2324011B1 (es) | Procedimiento para la obtencion de celulas madre mesenquimales a partir de la fraccion mononuclear de la medula osea humana. | |
CN105713872A (zh) | 间充质干细胞培养试剂盒 | |
CN112852727A (zh) | 一种人脐带来源Muse细胞的培养方法 | |
CN111893092A (zh) | 一种人脐带来源的间充质干细胞及其制备方法 | |
CN106011057A (zh) | 一种小鼠甲状腺间充质干细胞及其分离提取方法 | |
Chang et al. | In vitro Expansion of Mesenchymal Stem Cells using 3D Matrix Derived from Cardiac Fibroblast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980157235.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/003899 Country of ref document: MX |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09836102 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13124916 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011000942 Country of ref document: CL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11053413 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/007171 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5709/DELNP/2011 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09836102 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0919754 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0919754 Country of ref document: BR Free format text: APRESENTE DOCUMENTOS COMPROBATORIOS QUE EXPLIQUEM A DIVERGENCIA NO NOME DE UM DOS INVENTORES QUE CONSTA NA PUBLICACAO INTERNACIONAL WO2010/076349 DE 08/07/2010 "ARNAU PLA CALVET" E O CONSTANTE DA PETICAO INICIAL NO 020110041455 DE 26/04/2011 "PABLO ARNAU PLA CALVET". |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0919754 Country of ref document: BR Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2371 DE 14/06/2016. |